The global lidocaine jelly and gels market was valued at USD 166.1 Million in 2019 and is projected to reach USD 216.5 Million by 2027, expanding at a CAGR of 3.7% during the forecast period. Demand for lidocaine jelly and gels is driven by the multiple applications such as dentistry, urology, and tattoos, growth of OTC drugs segment, rising adoption of e-pharmacies, and increasing healthcare expenditure.
Lidocaine is one of the prominent and commonly used medications used to numb the tissues. It is available in jelly, gels, injectable, spray, and others forms. It is used for facilitating anesthesia for various surgical procedures. Lidocaine numbs the tissues by blocking sodium channels, which in turn, creates an invisible barrier between the neurons of local tissues and makes them incapable of signaling the brain. It is considered as class Ib anti-arrhythmic agent owing to its varied usage such as decreasing muscle contractions, resulting in effects like hypotension, and irregular heart rate.
Lidocaine jelly is prominently used during catheter insertion. The cases related to urinary catheter insertion is rising. The Lidocaine gels is a primary product used during long catheterizations, as patients need numbness to bear long treatment schedules, which in turn, fuels the need for lidocaine gels, thereby propelling the market during the forecast period.
Lidocaine jelly helps in to manage pain caused by different chronic diseases such as arthritis, urethritis, and others. Generally, the lidocaine gel is applied externally on the skin surface which is absorbed by the skin to numb and reduce the pain in the area. Rising incidence rate of chronic diseases, especially in densely populated countries such as India and China, fuels demand for Lidocaine jelly to treat chronic diseases. According to the National Center for Biotechnology Information, 33% of population in China and 49% of people India, aged 50 years and above, have been reported with at least one chronic condition. These figures proves the high need for Lidocaine jelly, which in turn, is expected to fuel the market during the forecast period.
The FDA has raised concerns regarding the usage of Lidocaine jelly and gels usage on infants and children, especially for tooth-related pains, as this can lead to serious implications such as seizures and brain damage. Various governmental bodies have raised concerns on the over usage of OTC Lidocaine jelly, as its extensive usage can lead to methemoglobinemia. Thus, implementation of rigid government regulations are likely to restrain the global lidocaine jelly and gels market. Medical companies are developing alternative methods and products to treat ailments of individuals. Furthermore, doctors are preferring anesthetic from the ester group as Lidocaine (a classified amide) is allergic to some patients. Additionally, easy availability of Tramadol, Gabapentin, and growing number of substitutes which serve the same purpose is likely to impede the market during the forecast period. Lidocaine is a local painkiller and a primary aid for many skin remedies. Besides this, Lidocaine is extensively used in cosmetic surgeries. Increase in the number of cosmetic surgeries boosts the demand for the jelly. Surge in the number of cosmetic surgeries is likely to create lucrative opportunities for Lidocaine jelly and gel manufacturers in the coming years.
On the basis of product types, the global lidocaine jelly and gels market has been bifurcated into Rx and OTC. The Rx segment is expected to hold a significant share of the market during the forecast period due to high adoption of prescription drugs, as prescription drugs enable patients to opt for treatments that are suitable to their health orientations and medical history. The OTC segment is anticipated to hold a key share of the market and is projected to expand at a substantial CAGR during the forecast period.
In terms of applications, the global lidocaine jelly and gels market has been segmented into interstitial cystitis/bladder pain syndrome, pain relief in urethritis and others. The interstitial cystitis/bladder pain syndrome segment is expected to hold a significant share of the market and is anticipated to expand at a considerable CAGR during the forecast period. The growth of this segment is attributed to the rising awareness regarding health among people and increasing incidences of bladder pain syndrome. The pain relief in urethritis segment is anticipated to account for a substantial share of the market and is projected to expand at a substantial CAGR during the forecast period. Growing usage of lidocaine gel for pain relief and rising number of cases of urethritis are boosting the segment’s growth.
Based on distribution channels, the global lidocaine jelly and gels market has been segregated into hospital pharmacy, retail pharmacy and e-commerce. The hospital pharmacy segment is expected to hold a significant share of the market and is anticipated to expand at a considerable CAGR during the forecast period. Hospitals carry out various surgeries, procedures, and treatments that utilize lidocaine jelly such as cystoscopy, cataract surgery, and endotracheal intubation, for which they use their pharmacy’s stock of drugs. This, in turn, is fueling the hospital pharmacy segment. The retail pharmacy segment is anticipated to account for a sizeable share of the market and is projected to expand at a substantial CAGR during the forecast period, owing to the rising number of developments in remote areas, growing population, easy access to pharmacies, and increasing use of lidocaine gel for pain relief are propelling the segment.
On the basis of regions, the global job description management software market is fragmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The US holds a substantial share of the market. The market in the country is expected to expand at a considerable CAGR during the forecast period. The demand for OTC drugs is rising in the US, as stores in the country often sell private label OTC products, which are extensively used due to the lower cost than the Rx products. Italy has the highest percentage of people adopting tattoos, which in turn, is propelling the market for lidocaine jelly and gels in the country.
Some frequently asked quetions about this report!
Additional company profiles are provided on request.
Yes, the report provides supply chain analysis along with a list of raw material suppliers, manufacturers, distributors, and customers.
According to the Growth Market Reports, the market for lidocaine jelly and gels is likely to register a CAGR of 3.7% during forecast period 2020-2027, with an anticipated valuation of USD 216.5 million by the end of 2027.
In addition to market size (in USD Million) and, company market share (in % for base year 2019), other data such as Impact of Key Regulations, Pipeline Analysis, macro-economic factors and COVID-19 impact on the value chain are available in the final report.
Applications in the global lidocaine jelly and gels market includes interstitial cystitis or bladder pain syndrome, pain relief in urethritis, arthritis, skin discomfort, and others.
Demand for lidocaine jelly and gels is expected to continue to increase over the forecast period, taking into account multiple applications such as dentistry, urology, and tattoos, growth of OTC drugs segment, rising adoption of e-pharmacies, and increasing healthcare expenditure.
Factors such as competitive strength and market positioning are key areas, which are considered while selecting top companies to be profiled.
The market is expected to decrease around 1.2% in 2020, owing to the negative impact of COVID-19 pandemic on the global lidocaine jelly and gels market.
The base year considered for the global lidocaine jelly and gels market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.
Major Manufactures are Akorn, Incorporated, Aspen Pharmacare Holdings Limited, AstraZeneca, Curatio Healthcare Private Limited, ESBA Laboratories Inc., and FARCO-PHARMA GmbH.
Some other reports from this category!